Trial
NCT01940887
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ophthotech Corporation
Collaborators
—
Condition
Age-Related Macular Degeneration
Intervention
E10030
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-31